• Je něco špatně v tomto záznamu ?

Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms

B. Ungar, K. Malickova, J. Hanžel, M. Abu Arisha, S. Paul, C. Rocha, Z. Ben Shatach, CM. Abitbol, O. Haj Natour, L. Selinger, M. Yavzori, E. Fudim, O. Picard, I. Shoval, R. Eliakim, U. Kopylov, F. Magro, X. Roblin, Y. Chowers, D. Drobne, M....

. 2021 ; 15 (10) : 1707-1719. [pub] 2021Oct07

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012106

Grantová podpora
Chaim Sheba Medical Center
Leona M. and Harry B. Helmsley Charitable Trust
PDE/BDE/114583/2016 Fundação para a Ciência e Tecnologia

BACKGROUND: Real life data regarding pharmacokinetics of vedolizumab in patients needing dose optimisation are scarce. We set to examine whether pre-optimisation vedolizumab levels associate with therapy outcomes and which mechanisms explain the associations. METHODS: A multicentre observational study assessed the outcome of dose increase in association with pre-escalation levels in vedolizumab-treated patients. SubsequentIy, α4β7 occupancy on peripheral blood [PB] and intestinal lamina propria [LP] tissues was investigated on various cellular subsets in patients undergoing lower endoscopy on infusion day. Cellular localisation of vedolizumab-bound α4β7 and effects on M1 and M2 macrophages were also explored. RESULTS: A total of 161 inflammatory bowel disease [IBD] patients were included. Among 129/161 patients intensified during maintenance [Week 14 onward], pre-intensification trough levels were comparable or higher among those subsequently attaining post-optimisation clinical, biomarker, and endoscopic remission, compared with non-remitting patients [p = 0.09, 0.25, 0.04, respectively]. Similar results were demonstrated for those dose-optimised during induction [Week 6, n = 32]. In the immune sub-study [n = 43], free α4β7 receptors at trough were similarly low among patients with/without mucosal healing, on PB T cells [p = 0.15], LP T cells [p = 0.88], and on PB eosinophils [p = 0.08]. Integrin receptors on M1 and M2 macrophages were also saturated by low levels of vedolizumab and anti-inflammatory cytokine secretion was not increased. Co-localisation and dissociation experiments demonstrated membranal α4β7 receptors of two origins: non-internalised and newly generated α4β7, but re-binding was still complete at very low concentrations. CONCLUSIONS: These results do not support pharmacokinetics as the mechanism responsible for loss of response to vedolizumab, nor do they support a need for higher drug concentration to enhance vedolizumab's immune effects. Higher pre-escalation levels may indicate less clearance [less severe disease] and higher likelihood of subsequent re-gained response, regardless of therapy escalation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012106
003      
CZ-PrNML
005      
20220506130805.0
007      
ta
008      
220425s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ecco-jcc/jjab067 $2 doi
035    __
$a (PubMed)33837762
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Ungar, Bella $u Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
245    10
$a Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms / $c B. Ungar, K. Malickova, J. Hanžel, M. Abu Arisha, S. Paul, C. Rocha, Z. Ben Shatach, CM. Abitbol, O. Haj Natour, L. Selinger, M. Yavzori, E. Fudim, O. Picard, I. Shoval, R. Eliakim, U. Kopylov, F. Magro, X. Roblin, Y. Chowers, D. Drobne, M. Lukas, S. Ben Horin
520    9_
$a BACKGROUND: Real life data regarding pharmacokinetics of vedolizumab in patients needing dose optimisation are scarce. We set to examine whether pre-optimisation vedolizumab levels associate with therapy outcomes and which mechanisms explain the associations. METHODS: A multicentre observational study assessed the outcome of dose increase in association with pre-escalation levels in vedolizumab-treated patients. SubsequentIy, α4β7 occupancy on peripheral blood [PB] and intestinal lamina propria [LP] tissues was investigated on various cellular subsets in patients undergoing lower endoscopy on infusion day. Cellular localisation of vedolizumab-bound α4β7 and effects on M1 and M2 macrophages were also explored. RESULTS: A total of 161 inflammatory bowel disease [IBD] patients were included. Among 129/161 patients intensified during maintenance [Week 14 onward], pre-intensification trough levels were comparable or higher among those subsequently attaining post-optimisation clinical, biomarker, and endoscopic remission, compared with non-remitting patients [p = 0.09, 0.25, 0.04, respectively]. Similar results were demonstrated for those dose-optimised during induction [Week 6, n = 32]. In the immune sub-study [n = 43], free α4β7 receptors at trough were similarly low among patients with/without mucosal healing, on PB T cells [p = 0.15], LP T cells [p = 0.88], and on PB eosinophils [p = 0.08]. Integrin receptors on M1 and M2 macrophages were also saturated by low levels of vedolizumab and anti-inflammatory cytokine secretion was not increased. Co-localisation and dissociation experiments demonstrated membranal α4β7 receptors of two origins: non-internalised and newly generated α4β7, but re-binding was still complete at very low concentrations. CONCLUSIONS: These results do not support pharmacokinetics as the mechanism responsible for loss of response to vedolizumab, nor do they support a need for higher drug concentration to enhance vedolizumab's immune effects. Higher pre-escalation levels may indicate less clearance [less severe disease] and higher likelihood of subsequent re-gained response, regardless of therapy escalation.
650    _2
$a dospělí $7 D000328
650    _2
$a humanizované monoklonální protilátky $x aplikace a dávkování $7 D061067
650    _2
$a biologické markery $x analýza $7 D015415
650    _2
$a C-reaktivní protein $x analýza $7 D002097
650    _2
$a molekuly buněčné adheze $x analýza $7 D015815
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a gastrointestinální endoskopie $7 D016099
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a gastrointestinální látky $x aplikace a dávkování $7 D005765
650    _2
$a lidé $7 D006801
650    _2
$a idiopatické střevní záněty $x farmakoterapie $7 D015212
650    _2
$a makrofágy $x účinky léků $7 D008264
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mukoproteiny $x analýza $7 D009088
650    _2
$a sérový albumin $x analýza $7 D012709
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Malickova, Karin $u IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic
700    1_
$a Hanžel, Jurij $u Department of Gastroenterology, University Medical Centre Ljubljana, Ljuljana, Slovenia $1 https://orcid.org/0000000331588014
700    1_
$a Abu Arisha, Muhammad $u Rambam Health Care Campus, Bruce and Ruth Rappaport Faculty of Medicine, Haifa, Israel
700    1_
$a Paul, Stephane $u Immunology Department, GIMAP CIC INSERM 1408, University of Lyon, Saint Etienne, France
700    1_
$a Rocha, Catia $u Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal $u Instituto de Saúde Ambiental, Faculty of Medicine, University of Lisbon, Lisbon, Portugal
700    1_
$a Ben Shatach, Zohar $u Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel $1 https://orcid.org/0000000172259765
700    1_
$a Abitbol, Chaya Mushka $u Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
700    1_
$a Haj Natour, Ola $u Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
700    1_
$a Selinger, Limor $u Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
700    1_
$a Yavzori, Miri $u Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
700    1_
$a Fudim, Ella $u Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
700    1_
$a Picard, Orit $u Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
700    1_
$a Shoval, Irit $u Mina and Everard Goodman Faculty of Life Sciences, Bar Ilan, Ramat Gan, Israel
700    1_
$a Eliakim, Rami $u Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
700    1_
$a Kopylov, Uri $u Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
700    1_
$a Magro, Fernando $u Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal
700    1_
$a Roblin, Xavier $u Department of Hepatogastroenterology, University Hospital of Saint Etienne, Saint Etienne, France
700    1_
$a Chowers, Yehuda $u Rambam Health Care Campus, Bruce and Ruth Rappaport Faculty of Medicine, Haifa, Israel
700    1_
$a Drobne, David $u Department of Gastroenterology, University Medical Centre Ljubljana, Ljuljana, Slovenia $u Medical Faculty, University of Ljubljana, Ljubljana, Slovenia $1 https://orcid.org/000000032734675X
700    1_
$a Lukas, Milan $u IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic
700    1_
$a Ben Horin, Shomron $u Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
773    0_
$w MED00166945 $t Journal of Crohn's & colitis $x 1876-4479 $g Roč. 15, č. 10 (2021), s. 1707-1719
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33837762 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130758 $b ABA008
999    __
$a ok $b bmc $g 1789622 $s 1163307
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 15 $c 10 $d 1707-1719 $e 2021Oct07 $i 1876-4479 $m Journal of Crohn's and colitis $n J Crohns Colitis $x MED00166945
GRA    __
$p Chaim Sheba Medical Center
GRA    __
$p Leona M. and Harry B. Helmsley Charitable Trust
GRA    __
$a PDE/BDE/114583/2016 $p Fundação para a Ciência e Tecnologia
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace